Bedaquiline, pretomanid, and linezolid in multidrug-resistant and pre-extensively drug-resistant tuberculosis in refugee
Janina Trauth, Vera Kantelhardt, Bohdan Usenko, Michael Knipper, Martin Kuhns, Inna Friesen, Susanne Herold
European Respiratory Journal 2024; DOI: 10.1183/13993003.00303-2024
Extract
According to the WHO 2023 tuberculosis report, in the European Union region there are approximately 200.000 tuberculosis cases per year, among which 30.000 are rifampicin-resistant with treatment success rates of 57% [1], indicating a considerable gap from the UN's goal of an 80% reduction by 2030.